Navigation Links
ImmunoVaccine Technologies Partners With Scancell to Advance DNA Vaccine Delivery
Date:8/5/2009

HALIFAX, NS, Aug. 5 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a Canadian vaccine development company, has signed an agreement with UK-based Scancell Ltd., the operating company of Scancell Holdings Plc (SCLP.PL), which is developing therapeutic cancer and infectious disease vaccines. This research agreement will explore the potential of using IVT's DepoVax(TM) delivery system for Scancell's novel ImmunoBody(R) DNA vaccines.

"Scancell is developing an exciting DNA vaccine technology and we are delighted to enter into this collaboration," remarked Dr. Marc Mansour, vice president of R D at IVT. "Our DepoVax(TM) technology has the potential to better deliver DNA vaccines to draining lymph nodes to produce high levels of immune response using conventional immunization techniques."

"IVT's DepoVax(TM) represents a potentially attractive future delivery system for our ImmunoBody(R) DNA vaccines, especially those for certain infectious diseases where alternative delivery methods such as electroporation may be less suitable." commented David Evans, chairman of Scancell.

DNA-based vaccines have gained popularity due to promising results reported the clinic, their relative ease of manufacture and potential for enhanced stability. There is currently a need for simple alternative methods of delivering DNA vaccines

DepoVax(TM) is a vaccine-enhancement and delivery platform comprised of liposomes, adjuvants and oil. DepoVax(TM) enhances the immunogenicity of antigens in general, and can be used to dramatically enhance the delivery of polynucleotide-based antigens and SiRNA to lymph nodes. IVT has proven its scale-up capabilities at a contract manufacturing plant, making DepoVax(TM) amenable to commercialization.

ImmunoVaccine Technologies continues to strengthen its vaccine pipeline through licensing and strategic partnering to develop therapeutic cancer and infection disease vaccines. In 2008, Pfizer Animal Health licensed its proprietary vaccine delivery technology for two livestock vaccines. With positive pre-clinical safety data and recent partnerships with LIAI, NIH, Yokohoma City University, Defence Research Development Canada, FIT Biotech, and Immunotope Inc. the value of Depovax(TM) has been significantly enhanced. www.immunovaccine.com.

Scancell is developing novel therapeutic vaccines for the treatment of cancer and infectious diseases based on its groundbreaking ImmunoBody(R) technology platform. Scancell's first cancer vaccine SCIB1 is being developed for the treatment of melanoma and will enter clinical trials using electroporation technology in early 2010.

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future are forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. IVT assumes no responsibility to update forward-looking statements in this press release.


'/>"/>
SOURCE IMMUNOVACCINE TECHNOLOGIES INC.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board
2. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
3. ImmunoVaccine Technologies Patents DepoVax(TM) Vaccine Platform
4. ImmunoVaccine Technologies Congratulates Dr. Ramila Philip as One of PAs Best 50 Women in Business
5. ImmunoVaccine Technologies Broadens Its Patent Protection to Japan
6. ImmunoVaccine Technologies Presents at OneMed Place Finance Forum
7. ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria
8. ImmunoVaccine Technologies Collaborates with Defence Research & Development Canada to Strengthen Canadas Ability to Deal with Biological Threats
9. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imagin
10. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imaging
11. ImmunoVaccine Technologies Partners with FIT Biotech to advance a therapeutic HIV vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... ... all six of their healthcare job boards. As the largest network of ... therapists, and biotechnicians, DocCafe.com and the MedJobCafe.com Health Network work to match ...
(Date:6/22/2017)... ... 2017 , ... Building on the success of the inaugural RAADfest last year, ... latest developments in radical life extension. RAADfest combines cutting edge science presented for a ... personal development, making it the largest most comprehensive and inclusive super longevity event in ...
(Date:6/22/2017)... ... June 22, 2017 , ... Tunnell Consulting’s ... biopharma and life sciences industries, continue to be in demand for their insights ... will be speaking on “The State of Information Governance in the Biopharmaceutical Industry” ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... the CTNext board of directors has formed a Higher Education Entrepreneurship Advisory Committee ... composed of institution presidents and other high-ranking representatives from 35 higher education institutions ...
Breaking Biology Technology:
(Date:5/16/2017)... -- Veratad Technologies, LLC ( www.veratad.com ), an innovative and ... solutions, announced today they will participate as a sponsor ... May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions of ... digital world, defining identity is critical to nearly every ...
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):